연구동향 분석

Nonalcoholic Fatty Liver Disease and Coronary Atherosclerosis : in association with Coronary Artery Calcification and Plaque Characteristics = 비알콜성 지방간이 관상동맥 죽상경화증에 미치는 영향

박효은 2022년

논문상세정보
인용/피인용
' Nonalcoholic Fatty Liver Disease and Coronary Atherosclerosis : in association with Coronary Artery Calcification and Plaque Characteristics = 비알콜성 지방간이 관상동맥 죽상경화증에 미치는 영향' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 의료과학 약
  • coronary artery disease
  • coronary calcium
  • coronary heart disease
  • coronary plaque
  • fatty liver
  • hepatic steatosis
  • non-alcoholic fatty liver disease
  • vulnerable plaque
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
4,090 0

0.0%

' Nonalcoholic Fatty Liver Disease and Coronary Atherosclerosis : in association with Coronary Artery Calcification and Plaque Characteristics = 비알콜성 지방간이 관상동맥 죽상경화증에 미치는 영향' 의 참고문헌

  • Using the coronary artery calcium score to predict coronary heart disease events : a systematic review and meta-analysis
  • The association between nonalcoholic fatty liver disease
    Kim BJ , Kim NH , Kim BS , Kang JH 123 ( 1 ) :54-61 . [2012]
  • Targher G. NAFLD : A multisystem disease
    Byrne CD 62 ( 1S ) : S47-S64 . [2015]
  • Should coronary calcium screening be used in cardiovascular prevention strategies ?
    Bonow RO . Clinical practice 361 ( 10 ) :990-7 . [2009]
  • Reiner Z. Dyslipidemias in the prevention of cardiovascular disease : Risks and causality .
  • Progression of coronary artery calcium and risk of first myocardial infarction in patients receiving cholesterol-lowering therapy
    Raggi P , Callister TQ , Shaw LJ 24 ( 7 ) :1272-7 . [2004]
  • Progression of NAFLD to diabetes mellitus , cardiovascular disease or cirrhosis
    Anstee QM , Targher G , Day CP . 10 ( 6 ) :330-44 . [2013]
  • Nonalcoholic fatty liver disease and vascular risk
    Bhatia LS , Curzen NP , Byrne CD 27 ( 4 ) :420-8 . [2012]
  • Nonalcoholic fatty liver disease and cardiovascular disease
    Liu H , Lu HY 20 ( 26 ) :8407-15 . [2014]
  • Nonalcoholic fatty liver disease : dyslipidemia , risk for cardiovascular complications , and treatment strategy
    Zhang QQ , Lu LG 3 ( 1 ) :78-84 [2015]
  • Nonalcoholic Fatty Liver Disease Is Associated with the Presence and Morphology of Subclinical Coronary Atherosclerosis
    Kang MK , Kang BH , Kim JH 56 ( 5 ) :1288-95 [2015]
  • Non-alcoholic fatty liver disease : a new and important cardiovascular risk factor ?
    Bhatia LS , Curzen NP , Calder PC , Byrne CD 33 ( 10 ) :1190-200 . [2012]
  • Long-term outcomes of nonalcoholic fatty liver disease
    Kwak MS , Kim D. 14 ( 2 ) :69-76 . [2015]
  • Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
  • Goebeler S. C-reactive protein in vulnerable coronary plaques .
    Norja S , Nuutila L , Karhunen PJ 60 ( 5 ) :545-8 . [2007]
  • Diagnosis and management of nonalcoholic fatty liver disease and its hemostatic/thrombotic and vascular complications
    Targher G , Byrne CD . 39 ( 2 ) :214-28 . [2013]
  • De Luca L. High-density lipoprotein levels and risk of cardiovascular events : A review
    Mureddu GF , Brandimarte F , 13 ( 9 ) :575-86 [2012]
  • Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States
    Kim D , Kim WR , Kim HJ , Therneau TM 57 ( 4 ) :1357-65 . [2013]
  • 94. den Dekker MA, de Smet K, de Bock GH, Tio RA, Oudkerk M, Vliegenthart R. Diagnostic performance of coronary CT angiography for stenosis detection according to calcium score: systematic review and meta-analysis. European radiology. 2012;22(12):2688-98.
    [2012]
  • 93. Ferraioli G, Tinelli C, Lissandrin R, Zicchetti M, Faliva M, Perna S, et al. Correlation of the controlled attenuation parameter with indices of liver steatosis in overweight or obese individuals: a pilot study. Eur J Gastroenterol Hepatol. 2015;27(3):305-12.
    [2015]
  • 92. Kim JK, Lee KS, Choi JR, Chung HJ, Jung DH, Lee KA, et al. Usefulness of the controlled attenuation parameter for detecting liver steatosis in health checkup examinees. Gut Liver. 2015;9(3):405- 10.
    [2015]
  • 91. Kubo T, Matsuo Y, Hayashi Y, Yamano T, Tanimoto T, Ino Y, et al. High-sensitivity C-reactive protein and plaque composition in patients with stable angina pectoris: a virtual histology intravascular ultrasound study. Coron Artery Dis. 2009;20(8):531-5.
    [2009]
  • 9. Choi SY, Kim D, Kim HJ, Kang JH, Chung SJ, Park MJ, et al. The relation between non-alcoholic fatty liver disease and the risk of coronary heart disease in Koreans. The American journal of gastroenterology. 2009;104(8):1953-60.
    [2009]
  • 89. Burke AP, Tracy RP, Kolodgie F, Malcom GT, Zieske A, Kutys R, et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation. 2002;105(17):2019-23.
    [2002]
  • 88. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107(3):363-9.
    [2003]
  • 87. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350(14):1387-97.
    [2004]
  • 86. Yener S, Akarsu M, Demir T, Akinci B, Sagol O, Bayraktar F, et al. Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis. J Endocrinol Invest. 2007;30(10):810-9.
    [2007]
  • 85. Targher G. Relationship between high-sensitivity C-reactive protein levels and liver histology in subjects with non-alcoholic fatty liver disease. J Hepatol. 2006;45(6):879-81; author reply 81-2.
    [2006]
  • 84. Targher G, Bertolini L, Scala L, Zoppini G, Zenari L, Falezza G. Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue. Diabet Med. 2005;22(10):1354-8.
    [2005]
  • 82. Papatheodoridis GV, Chrysanthos N, Cholongitas E, Pavlou E, Apergis G, Tiniakos DG, et al. Thrombotic risk factors and liver histologic lesions in non-alcoholic fatty liver disease. J Hepatol. 2009;51(5):931-8.
    [2009]
  • 81. Carson AP, Steffes MW, Carr JJ, Kim Y, Gross MD, Carnethon MR, et al. Hemoglobin a1c and the progression of coronary artery calcification among adults without diabetes. Diabetes care. 2015;38(1):66-71.
    [2015]
  • 80. Puchner SB, Lu MT, Mayrhofer T, Liu T, Pursnani A, Ghoshhajra BB, et al. High-risk coronary plaque at coronary CT angiography is associated with nonalcoholic fatty liver disease, independent of coronary plaque and stenosis burden: results from the ROMICAT II trial. Radiology. 2015;274(3):693-701.
    [2015]
  • 8. Marano R, De Cobelli F, Floriani I, Becker C, Herzog C, Centonze M, et al. Italian multicenter, prospective study to evaluate the negative predictive value of 16- and 64-slice MDCT imaging in patients scheduled for coronary angiography (NIMISCAD-Non Invasive Multicenter Italian Study for Coronary Artery Disease). Eur Radiol. 2009;19(5):1114-23.
    [2009]
  • 79. Assy N, Djibre A, Farah R, Grosovski M, Marmor A. Presence of coronary plaques in patients with nonalcoholic fatty liver disease. Radiology. 2010;254(2):393-400.
    [2010]
  • 77. Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, Gramlich T, et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2009;7(2):234-8.
    [2009]
  • 75. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44(4):865-73.
    [2006]
  • 74. Dam-Larsen S, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, Sorensen TI, et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut. 2004;53(5):750-5.
    [2004]
  • 73. DeFilippis AP, Blaha MJ, Martin SS, Reed RM, Jones SR, Nasir K, et al. Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2013;227(2):429-36.
    [2013]
  • 70. Chatrath H, Vuppalanchi R, Chalasani N. Dyslipidemia in patients with nonalcoholic fatty liver disease. Semin Liver Dis 2012;32(1):22-9
    [2012]
  • 7. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50(8):1844-50.
    [2001]
  • 68. Wong VW, Wong GL, Yip GW, Lo AO, Limquiaco J, Chu WC, et al. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut. 2011;60(12):1721-7.
    [2011]
  • 64. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med. 2010;363(14):1341-50.
    [2010]
  • 62. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology. 2010;56(25):e50-103.
    [2010]
  • 60. Kronmal RA, McClelland RL, Detrano R, Shea S, Lima JA, Cushman M, et al. Risk factors for the progression of coronary artery calcification in asymptomatic subjects: results from the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2007;115(21):2722- 30.
    [2007]
  • 59. Rhee EJ, Kim JH, Park HJ, Park SE, Oh HG, Park CY, et al. Increased risk for development of coronary artery calcification in insulin-resistant subjects who developed diabetes: 4-year longitudinal study. Atherosclerosis. 2016;245:132-8.
    [2016]
  • 58. LaMonte MJ, FitzGerald SJ, Church TS, Barlow CE, Radford NB, Levine BD, et al. Coronary artery calcium score and coronary heart disease events in a large cohort of asymptomatic men and women. American journal of epidemiology. 2005;162(5):421-9.
    [2005]
  • 57. Achenbach S, Moselewski F, Ropers D, Ferencik M, Hoffmann U, MacNeill B, et al. Detection of calcified and noncalcified coronary atherosclerotic plaque by contrast-enhanced, submillimeter multidetector spiral computed tomography: a segment-based comparison with intravascular ultrasound. Circulation. 2004;109(1):14-7.
    [2004]
  • 56. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Jr., Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. Journal of the American College of Cardiology. 1990;15(4):827-32.
    [1990]
  • 55. Kwak MS, Chung GE, Yang JI, Yim JY, Chung SJ, Jung SY, et al. Clinical implications of controlled attenuation parameter in a health check-up cohort. Liver Int. 2018;38(5):915-23.
    [2018]
  • 54. Kwok R, Choi KC, Wong GL, Zhang Y, Chan HL, Luk AO, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut. 2016;65(8):1359-68.
    [2016]
  • 53. Boursier J, Zarski JP, de Ledinghen V, Rousselet MC, Sturm N, Lebail B, et al. Determination of reliability criteria for liver stiffness evaluation by transient elastography. Hepatology. 2013;57(3):1182-91.
    [2013]
  • 52. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29(12):1705-13.
    [2003]
  • 51. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123(3):745-50.
    [2002]
  • 50. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010;59(9):1265-9.
    [2010]
  • 5. Ndumele CE, Nasir K, Conceicao RD, Carvalho JA, Blumenthal RS, Santos RD. Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation. Arteriosclerosis, thrombosis, and vascular biology. 2011;31(8):1927-32.
    [2011]
  • 49. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007;46(1):32-6.
    [2007]
  • 48. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518-26.
    [2003]
  • 46. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142(7):1592-609.
    [2012]
  • 45. You SC, Kim KJ, Kim SU, Kim BK, Park JY, Kim DY, et al. Hepatic fibrosis assessed using transient elastography independently associated with coronary artery calcification. J Gastroenterol Hepatol. 2015;30(10):1536-42.
    [2015]
  • 44. de Ledinghen V, Vergniol J, Foucher J, Merrouche W, le Bail B. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int. 2012;32(6):911-8.
    [2012]
  • 43. Myers RP, Pollett A, Kirsch R, Pomier-Layrargues G, Beaton M, Levstik M, et al. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int. 2012;32(6):902-10.
    [2012]
  • 42. Recio E, Cifuentes C, Macias J, Mira JA, Parra-Sanchez M, Rivero-Juarez A, et al. Interobserver concordance in controlled attenuation parameter measurement, a novel tool for the assessment of hepatic steatosis on the basis of transient elastography. Eur J Gastroenterol Hepatol. 2013;25(8):905-11.
    [2013]
  • 41. Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcellin P, Poupon R, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36(11):1825-35.
  • 40. Karlas T, Petroff D, Sasso M, Fan JG, Mi YQ, de Ledinghen V, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022-30.
    [2017]
  • 4. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. The American journal of medicine. 1999;107(5):450-5.
    [1999]
  • 38. Osawa K, Miyoshi T, Yamauchi K, Koyama Y, Nakamura K, Sato S, et al. Nonalcoholic Hepatic Steatosis Is a Strong Predictor of High-Risk Coronary-Artery Plaques as Determined by Multidetector CT. PLoS One. 2015;10(6):e0131138.
    [2015]
  • 37. Hausleiter J, Meyer T, Hadamitzky M, Kastrati A, Martinoff S, Schomig A. Prevalence of noncalcified coronary plaques by 64-slice computed tomography in patients with an intermediate risk for significant coronary artery disease. J Am Coll Cardiol. 2006;48(2):312-8.
    [2006]
  • 36. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation. 2003;108(15):1772-8.
    [2003]
  • 35. van Velzen JE, de Graaf FR, Jukema JW, de Grooth GJ, Pundziute G, Kroft LJ, et al. Comparison of the relation between the calcium score and plaque characteristics in patients with acute coronary syndrome versus patients with stable coronary artery disease, assessed by computed tomography angiography and virtual histology intravascular ultrasound. Am J Cardiol. 2011;108(5):658- 64.
  • 34. Yoon YE, Chang SA, Choi SI, Chun EJ, Cho YS, Youn TJ, et al. The absence of coronary artery calcification does not rule out the presence of significant coronary artery disease in Asian patients with acute chest pain. Int J Cardiovasc Imaging. 2012;28(2):389-98.
    [2012]
  • 33. Budoff MJ, Shaw LJ, Liu ST, Weinstein SR, Mosler TP, Tseng PH, et al. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol. 2007;49(18):1860-70.
    [2007]
  • 31. Schindhelm RK, Dekker JM, Nijpels G, Bouter LM, Stehouwer CD, Heine RJ, et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis. 2007;191(2):391-6.
    [2007]
  • 30. Wai-Sun Wong V, Lai-Hung Wong G, Ching-Lam Yeung J, Yuk-Kiu Fung C, Ka-Lei Chan J, Hoi-Yi Chang Z, et al. Long-term clinical outcomes after fatty liver screening in patients undergoing coronary angiogram: a prospective cohort study. Hepatology. 2015; 63(3):754-63.
    [2015]
  • 3. Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology. 2005;42(2):473-80.
    [2005]
  • 29. Kapuria D, Takyar VK, Etzion O, Surana P, O'Keefe JH, Koh C. Association of Hepatic Steatosis With Subclinical Atherosclerosis: Systematic Review and Meta-Analysis. Hepatol Commun. 2018;2(8):873-83.
    [2018]
  • 28. Raggi P, Cooil B, Shaw LJ, Aboulhson J, Takasu J, Budoff M, et al. Progression of coronary calcium on serial electron beam tomographic scanning is greater in patients with future myocardial infarction. The American journal of cardiology. 2003;92(7):827-9.
    [2003]
  • 26. McEvoy JW, Blaha MJ, Defilippis AP, Budoff MJ, Nasir K, Blumenthal RS, et al. Coronary artery calcium progression: an important clinical measurement? A review of published reports. Journal of the American College of Cardiology. 2010;56(20):1613- 22.
    [2010]
  • 25. Budoff MJ, Hokanson JE, Nasir K, Shaw LJ, Kinney GL, Chow D, et al. Progression of coronary artery calcium predicts all-cause mortality. JACC Cardiovascular imaging. 2010;3(12):1229-36.
    [2010]
  • 24. Hou ZH, Lu B, Gao Y, Jiang SL, Wang Y, Li W, et al. Prognostic value of coronary CT angiography and calcium score for major adverse cardiac events in outpatients. JACC Cardiovascular imaging. 2012;5(10):990-9.
    [2012]
  • 23. Otton JM, Yu CY, McCrohon J, Sammel N, Feneley M. Accuracy and clinical outcomes of computed tomography coronary angiography in the presence of a high coronary calcium score. Heart, lung & circulation. 2013;22(12):980-6.
    [2013]
  • 22. Kramer CK, Zinman B, Gross JL, Canani LH, Rodrigues TC, Azevedo MJ, et al. Coronary artery calcium score prediction of all cause mortality and cardiovascular events in people with type 2 diabetes: systematic review and meta-analysis. BMJ. 2013;346:f1654.
    [2013]
  • 21. Greenland P, Lloyd-Jones DM. Role of Coronary Artery Calcium Testing for Risk Assessment in Primary Prevention of Atherosclerotic Cardiovascular Disease: A Review. JAMA Cardiol. 2021 Oct 6. Online ahead of print.
    [2021]
  • 20. Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 2004;291(2):210-5.
    [2004]
  • 2. Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of nonalcoholic fatty liver disease. Clinical and molecular hepatology. 2013;19(4):325-48.
    [2013]
  • 19. Toth PP. Subclinical atherosclerosis: what it is, what it means and what we can do about it. Int J Clin Pract. 2008;62(8):1246-54.
    [2008]
  • 18. Berry JD, Liu K, Folsom AR, Lewis CE, Carr JJ, Polak JF, et al. Prevalence and progression of subclinical atherosclerosis in younger adults with low short-term but high lifetime estimated risk for cardiovascular disease: the coronary artery risk development in young adults study and multi-ethnic study of atherosclerosis. Circulation. 2009;119(3):382-9.
    [2009]
  • 17. Park HE, Lee H, Choi SY, Kwak MS, Yang JI, Yim JY, et al. Usefulness of controlled attenuation parameter for detecting increased arterial stiffness in general population. Dig Liver Dis. 2018;50(10):1062-7.
    [2018]
  • 16. Lee YJ, Shim JY, Moon BS, Shin YH, Jung DH, Lee JH, et al. The relationship between arterial stiffness and nonalcoholic fatty liver disease. Dig Dis Sci. 2012;57(1):196-203.
    [2012]
  • 15. Chen JY, Chou CH, Tsai WC, Wang MC, Ho CS, Li YH, et al. Effects of increased systemic inflammation and central obesity on arterial stiffness in patients with nonalcoholic fatty liver disease. J Am Soc Hypertens. 2012;6(4):253-60.
    [2012]
  • 13. Meyer ML, Tanaka H, Palta P, Cheng S, Gouskova N, Aguilar D, et al. Correlates of Segmental Pulse Wave Velocity in Older Adults: The Atherosclerosis Risk in Communities (ARIC) Study. Am J Hypertens. 2016;29(1):114-22.
    [2016]
  • 12. Akabame S, Hamaguchi M, Tomiyasu K, Tanaka M, Kobayashi-Takenaka Y, Nakano K, et al. Evaluation of vulnerable coronary plaques and non-alcoholic fatty liver disease (NAFLD) by 64-detector multislice computed tomography (MSCT). Circ J. 2008;72(4):618-25.
    [2008]
  • 11. Choi SY, Kim D, Kang JH, Park MJ, Kim YS, Lim SH, et al. Nonalcoholic fatty liver disease as a risk factor of cardiovascular disease: relation of non-alcoholic fatty liver disease to carotid atherosclerosis. The Korean journal of hepatology. 2008;14(1):77- 88.
    [2008]
  • 10. Kim D, Choi SY, Park EH, Lee W, Kang JH, Kim W, et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology. 2012;56(2):605-13.
    [2012]
  • 1. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005-23.
    [2012]